PH12022553464A1 - Adjuvant with tlr4 agonist activity - Google Patents

Adjuvant with tlr4 agonist activity

Info

Publication number
PH12022553464A1
PH12022553464A1 PH1/2022/553464A PH12022553464A PH12022553464A1 PH 12022553464 A1 PH12022553464 A1 PH 12022553464A1 PH 12022553464 A PH12022553464 A PH 12022553464A PH 12022553464 A1 PH12022553464 A1 PH 12022553464A1
Authority
PH
Philippines
Prior art keywords
adjuvant
agonist activity
tlr4 agonist
compound
vaccine adjuvant
Prior art date
Application number
PH1/2022/553464A
Other languages
English (en)
Inventor
Hitoshi Ban
Akihisa Fukushima
Yusuke Imazaki
Yosuke Takanashi
Original Assignee
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma Co Ltd filed Critical Sumitomo Pharma Co Ltd
Publication of PH12022553464A1 publication Critical patent/PH12022553464A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/24Condensed ring systems having three or more rings
    • C07H15/248Colchicine radicals, e.g. colchicosides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • C07H1/06Separation; Purification
    • C07H1/08Separation; Purification from natural products
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06Aminosugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PH1/2022/553464A 2020-06-22 2021-06-21 Adjuvant with tlr4 agonist activity PH12022553464A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020107194 2020-06-22
PCT/JP2021/023402 WO2021261444A1 (ja) 2020-06-22 2021-06-21 Tlr4作動活性を有するアジュバント

Publications (1)

Publication Number Publication Date
PH12022553464A1 true PH12022553464A1 (en) 2024-03-04

Family

ID=79281148

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2022/553464A PH12022553464A1 (en) 2020-06-22 2021-06-21 Adjuvant with tlr4 agonist activity

Country Status (15)

Country Link
US (1) US20230287027A1 (https=)
EP (1) EP4169527A4 (https=)
JP (1) JPWO2021261444A1 (https=)
KR (1) KR20230026438A (https=)
CN (1) CN116056721A (https=)
AU (1) AU2021295796A1 (https=)
BR (1) BR112022025969A2 (https=)
CA (1) CA3187828A1 (https=)
CL (1) CL2022003689A1 (https=)
IL (1) IL299253A (https=)
MX (1) MX2022016181A (https=)
PE (1) PE20230463A1 (https=)
PH (1) PH12022553464A1 (https=)
SA (1) SA522441781B1 (https=)
WO (1) WO2021261444A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026018889A1 (ja) * 2024-07-19 2026-01-22 住友ファーマ株式会社 ワクチンアジュバントを含むリポソーム製剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
ATE518874T1 (de) 1999-11-15 2011-08-15 Oncothyreon Inc Synthetische lipid-a analogen und verwendungen davon
CN101863930A (zh) 2003-01-06 2010-10-20 科里克萨有限公司 一些氨烷基氨基葡糖苷磷酸酯化合物和它们的用途
US7807720B2 (en) 2007-02-01 2010-10-05 Panthera Biopharma, Llc Hydroxamic acid derivatives of 3-phenyl propionic acids useful as therapeutic agents for treating anthrax poisoning
CN105188710A (zh) * 2013-03-15 2015-12-23 葛兰素史密丝克莱恩生物有限公司 包含缓冲的氨基烷基氨基葡糖苷磷酸酯衍生物的组合物及其用于增强免疫应答的用途
EP3242883A4 (en) * 2015-01-06 2018-10-17 ImmunoVaccine Technologies Inc. Lipid a mimics, methods of preparation, and uses thereof
JP7362667B2 (ja) * 2018-02-12 2023-10-17 イニミューン・コーポレーション Toll様受容体リガンド

Also Published As

Publication number Publication date
CN116056721A (zh) 2023-05-02
BR112022025969A2 (pt) 2023-01-17
PE20230463A1 (es) 2023-03-14
EP4169527A4 (en) 2025-03-05
MX2022016181A (es) 2023-02-13
CL2022003689A1 (es) 2023-07-28
SA522441781B1 (ar) 2024-08-11
CA3187828A1 (en) 2021-12-30
US20230287027A1 (en) 2023-09-14
JPWO2021261444A1 (https=) 2021-12-30
IL299253A (en) 2023-02-01
WO2021261444A1 (ja) 2021-12-30
EP4169527A1 (en) 2023-04-26
KR20230026438A (ko) 2023-02-24
AU2021295796A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
SA522433155B1 (ar) مركبات ثلاثية الحلقة مستبدلة
SA520411222B1 (ar) مركبات بوصفها معدلات لعامل باديء حقيقي النواة 2ب وتركيبات وطرق
MX2023004157A (es) Composiciones de oligosacaridos para el uso como alimento para animales y sus metodos para producirlas.
EA201171481A1 (ru) Способ получения высококонцентрированного препарата иммуноглобулина для подкожного применения
PH12019500731A1 (en) Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
PH12019502093A1 (en) Novel ester compounds, method for the production thereof and use thereof
MX2023011464A (es) Inhibidores de la cinasa relacionada con el gen nunca en mitosis a 7 (nek7).
ZA202304541B (en) Cdk inhibitors and their use as pharmaceuticals
BR112023015721A2 (pt) Derivados tricíclicos úteis como inibidores de parp7
PH12021551057A1 (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
NZ746906A (en) Oxaborole esters and uses thereof
ZA202211168B (en) Fragrance composition
MX2023001504A (es) Compuestos como inhibidores del receptor del componente complemento 5a (c5ar).
ZA202401405B (en) Compositions and methods for anti-pacap antibodies
PH12022553464A1 (en) Adjuvant with tlr4 agonist activity
JOP20200327A1 (ar) مركبات سيانوتريازول واستخداماتها
MX2025012705A (es) Complejos cristalinos entre velagliflozina y agentes formadores de cocristales seleccionados, metodos para su preparacion y su uso en la preparacion de medicamentos
MX2021012200A (es) Adyuvante soluble en agua y composición que contiene el mismo.
GEAP202415862A (en) Alcohol derivatives as kv7 potassium channel openers
ZA202309924B (en) Amarouciaxanthin a esters and uses thereof
WO2021041495A3 (en) Method to maintain or enhance tissue
WO2019202345A3 (en) Process for the preparation of iloprost
NZ796802A (en) Novel compounds having inhibitory activity on prostaglandin e2 receptor and uses thereof
WO2020055359A3 (en) Oral dosage form of sorafenib tosylate
PH12021550248A1 (en) Borate of azetidine derivative